Literature DB >> 31611067

Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Herbert Lannon1, Shrijal S Shah1, Leny Dias1, Daniel Blackler1, Seth L Alper2, Martin R Pollak2, David J Friedman3.   

Abstract

The Apolipoprotein L1 (APOL1) risk variants G1 and G2 are associated with high rates of kidney disease in African Americans in genetic studies. However, our understanding of APOL1 biology has lagged far behind. Here we report that engineering G1 and G2 mutations on unnatural haplotype backgrounds instead of on the specific G1 and G2 haplotype backgrounds that occur in nature profoundly alters APOL1-mediated cytotoxicity in experimental systems. Thus, in addition to helping resolve some important controversies in the APOL1 field, our demonstration of the critical influence of haplotype background may apply more generally to the study of other genetic variants that cause or predispose to human disease.
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOL1; chronic kidney disease; focal segmental glomerulosclerosis; haplotype; trypanosome

Year:  2019        PMID: 31611067      PMCID: PMC6907738          DOI: 10.1016/j.kint.2019.07.010

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Authors:  Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

3.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

4.  Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.

Authors:  Daniel Granado; Daria Müller; Vanessa Krausel; Etty Kruzel-Davila; Christian Schuberth; Melanie Eschborn; Roland Wedlich-Söldner; Karl Skorecki; Hermann Pavenstädt; Ulf Michgehl; Thomas Weide
Journal:  J Am Soc Nephrol       Date:  2017-07-10       Impact factor: 10.121

5.  APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.

Authors:  Yulong Fu; Jun-Yi Zhu; Adam Richman; Yi Zhang; Xuefang Xie; Jharna R Das; Jinliang Li; Patricio E Ray; Zhe Han
Journal:  J Am Soc Nephrol       Date:  2016-11-18       Impact factor: 10.121

6.  APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.

Authors:  Etty Kruzel-Davila; Revital Shemer; Ayala Ofir; Ira Bavli-Kertselli; Ilona Darlyuk-Saadon; Pazit Oren-Giladi; Walter G Wasser; Daniella Magen; Eid Zaknoun; Maya Schuldiner; Adi Salzberg; Daniel Kornitzer; Zvonimir Marelja; Matias Simons; Karl Skorecki
Journal:  J Am Soc Nephrol       Date:  2016-11-18       Impact factor: 10.121

7.  Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu.

Authors:  Xiqian Lan; Hongxiu Wen; Moin A Saleem; Joanna Mikulak; Ashwani Malhotra; Karl Skorecki; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-03-18       Impact factor: 3.362

8.  APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.

Authors:  Lijun Ma; Jeff W Chou; James A Snipes; Manish S Bharadwaj; Ann L Craddock; Dongmei Cheng; Allison Weckerle; Snezana Petrovic; Pamela J Hicks; Ashok K Hemal; Gregory A Hawkins; Lance D Miller; Anthony J A Molina; Carl D Langefeld; Mariana Murea; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

Review 9.  Apolipoprotein L1 and Kidney Disease in African Americans.

Authors:  David J Friedman; Martin R Pollak
Journal:  Trends Endocrinol Metab       Date:  2016-03-03       Impact factor: 12.015

10.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

View more
  18 in total

1.  Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-lining residues within the C-terminal domain.

Authors:  Charles Schaub; Joseph Verdi; Penny Lee; Nada Terra; Gina Limon; Jayne Raper; Russell Thomson
Journal:  J Biol Chem       Date:  2020-07-29       Impact factor: 5.157

2.  Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity.

Authors:  Joseph A Giovinazzo; Russell P Thomson; Nailya Khalizova; Patrick J Zager; Nirav Malani; Enrique Rodriguez-Boulan; Jayne Raper; Ryan Schreiner
Journal:  Elife       Date:  2020-05-19       Impact factor: 8.140

3.  Complexities of Understanding Function from CKD-Associated DNA Variants.

Authors:  Jennie Lin; Katalin Susztak
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-08       Impact factor: 8.237

4.  GWAS in Mice Maps Susceptibility to HIV-Associated Nephropathy to the Ssbp2 Locus.

Authors:  Nicholas J Steers; Yask Gupta; Vivette D D'Agati; Tze Y Lim; Natalia DeMaria; Anna Mo; Judy Liang; Kelsey O Stevens; Dina F Ahram; Wan Yee Lam; Mihai Gagea; Lalitha Nagarajan; Simone Sanna-Cherchi; Ali G Gharavi
Journal:  J Am Soc Nephrol       Date:  2021-12-10       Impact factor: 10.121

5.  APOL1 risk variants in kidney transplantation: a modulation of immune cell function.

Authors:  Andrew F Malone
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

6.  Cation Channel Activity of Apolipoprotein L1 is Modulated by Haplotype Background.

Authors:  Rebecca L Winkler; Jonathan Bruno; Paula Buchanan; John C Edwards
Journal:  J Am Soc Nephrol       Date:  2022-07-15       Impact factor: 14.978

Review 7.  APOL1 Nephropathy: From Genetics to Clinical Applications.

Authors:  David J Friedman; Martin R Pollak
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-02       Impact factor: 8.237

Review 8.  Apolipoprotein L1 and mechanisms of kidney disease susceptibility.

Authors:  Leslie A Bruggeman; John R Sedor; John F O'Toole
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 2.894

9.  APOL1 at 10 years: progress and next steps.

Authors:  Barry I Freedman; Jeffrey B Kopp; Matthew G Sampson; Katalin Susztak
Journal:  Kidney Int       Date:  2021-03-29       Impact factor: 18.998

10.  JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.

Authors:  Sarah E Nystrom; Guojie Li; Somenath Datta; Karen L Soldano; Daniel Silas; Astrid Weins; Gentzon Hall; David B Thomas; Opeyemi A Olabisi
Journal:  JCI Insight       Date:  2022-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.